PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer

Xianping Xu(Affiliated Hospital of Southwest Medical University), Zhibin Luo(Southwest Medical University), Qiang Gong(Army Medical University), Linqiong Zhao(First People's Hospital of Chongqing), Yü Liu(Changhua Christian Hospital), Wei Wei(Zhujiang Hospital), Le Ma(Xi'an Jiaotong University)
Cancer Chemotherapy and Pharmacology
April 12, 2024
10.1007/s00280-024-04668-2
Cited by 7

Related Papers

Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries
|New England Journal of Medicine|2014|993
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety
|癌症：英文版|2018|189